TY - JOUR
TI - A Rare Case of Dulaglutide-Associated Angioedema in a Male Patient
AU - Karakousis, Nikolaos
AU - Kostakopoulos, Nikolaos A.
AU - Georgakopoulou,
AU - Vasiliki E.
AU - Pyrgioti, Elisavet E.
AU - Georgakopoulos, Petros N.
JO - CUREUS
PY - 2021
VL - 13
TODO - 11
SP - null
PB - CUREUS INC
SN - null
TODO - 10.7759/cureus.20041
TODO - swelling; angioedema; type 2 diabetes; dulaglutide; glucagon-like
peptide-1 receptor agonist
TODO - Dulaglutide is an injectable glucagon-like peptide-1 receptor agonist
approved for the treatment of adults with type 2 diabetes. Angioedema is
defined as self-limiting edema, localized in the deeper layers of the
skin and mucosa. Angioedema can be hereditary or acquired which can be
allergic due to reactions to foods, insect bites and stings, and latex,
drug-induced, caused by physical stimuli and associated with lupus
erythematosus and hypereosinophilia. Angioedema represents a rare
adverse event of glucagon-like peptide-1 receptor agonists. The only
glucagon-like peptide-1 receptor agonist that has been mentioned to
induce angioedema in literature is exenatide. We report the first case
of dulaglutide-associated angioedema in a 72-year-old male in order to
point out to the clinicians this potential rare side effect of this drug
and its clinical significance.
ER -